Isoflurane
(Synonyms: 异氟醚) 目录号 : GC45487
Isoflurane是一种广泛应用的吸入麻醉药,具有强效麻醉、起效迅速和清除快的特点。
Cas No.:26675-46-7
Sample solution is provided at 25 µL, 10mM.
Isoflurane is a widely used inhalational anesthetic with a potent anesthetic effect, rapid onset, and quick elimination[1]. Isoflurane plays an important therapeutic role in cerebral ischemia-reperfusion injury by regulating the production of vascular endothelial growth factor (VEGF) and CD34 via the sonic hedgehog (Shh)/Gli signaling pathway[2]. Isoflurane inhibits electron transfer in respiratory complex I, with concerted downstream effects on membrane potential, ATP availability, and reactive oxygen species (ROS) flux[3]. After 2h of Isoflurane exposure, the human ovarian epithelial carcinoma cell line SK-OV3 and the non-small-cell lung carcinoma (NSCLC) lines A549 and H1299 all exhibited significantly enhanced proliferation and migration[4-5]. In C57/BL/6J mice, a 2h inhalation of 1.4% Isoflurane produced a marked increase in Bax mRNA and protein expression (protein rose from 100% to 170%) and a concurrent decrease in Bcl-2 mRNA and protein expression (protein fell from 100% to 61%) in neurons[6]. Compared with the cerebral ischemia–reperfusion (I/R) injury group, rats inhaling 1.5% or 3.0% Isoflurane for 60min showed markedly lower neurobehavioral deficit scores and smaller infarct volumes[7].
References:
[1] Saha P, Das A, Chatterjee N, et al. Impact of anesthetics on oncogenic signaling network: a review on propofol and isoflurane. Fundam Clin Pharmacol. 2022;36(1):49-71.
[2] Chen SJ, Yuan XQ, Xue Q, et al. Current research progress of isoflurane in cerebral ischemia/reperfusion injury: a narrative review. Med Gas Res. 2022;12(3):73-76.
[3] Rodriguez E, Peng B, Lane N. Anaesthetics disrupt complex I-linked respiration and reverse the ATP synthase. Biochim Biophys Acta Bioenerg. 2025;1866(1):149511.
[4] Iwasaki M, Zhao H, Jaffer T, et al. Volatile anaesthetics enhance the metastasis related cellular signalling including CXCR2 of ovarian cancer cells. Oncotarget. 2016;7(18):26042-26056.
[5] Zhang W, Shao X. Isoflurane Promotes Non-Small Cell Lung Cancer Malignancy by Activating the Akt-Mammalian Target of Rapamycin (mTOR) Signaling Pathway. Med Sci Monit. 2016;22:4644-4650.
[6] Zhang Y, Dong Y, Wu X, et al. The mitochondrial pathway of anesthetic isoflurane-induced apoptosis. J Biol Chem. 2010;285(6):4025-4037.
[7] Wang S, Yin J, Ge M, et al. Transforming growth-beta 1 contributes to isoflurane postconditioning against cerebral ischemia-reperfusion injury by regulating the c-Jun N-terminal kinase signaling pathway. Biomed Pharmacother. 2016;78:280-290.
Isoflurane是一种广泛应用的吸入麻醉药,具有强效麻醉、起效迅速和清除快的特点[1]。在脑缺血-再灌注损伤中,Isoflurane通过调控sonic hedgehog (Shh)/Gli信号通路,调节血管内皮生长因子(VEGF)和CD34的产生,发挥重要治疗作用[2]。Isoflurane可抑制呼吸链复合体I的电子传递,进而影响膜电位、ATP供应和活性氧(ROS)通量[3]。人卵巢上皮癌细胞系SK-OV3以及非小细胞肺癌细胞系A549和H1299在暴露于Isoflurane 2小时后,增殖与迁移能力均显著增强[4-5]。在C57/BL/6J小鼠中,吸入1.4%的Isoflurane 2小时可使神经元Bax mRNA及蛋白表达显著升高(蛋白水平由100%升至170%),同时Bcl-2 mRNA及蛋白表达显著降低(蛋白水平由100%降至61%)[6]。与单纯脑缺血-再灌注(I/R)损伤组相比,吸入1.5%或3.0%的Isoflurane 60分钟的大鼠神经行为学评分明显降低,脑梗死体积显著缩小[7]。
该计划仅提供一个指导方案,请根据具体需求进行修改。
Isoflurane处理动物[1]:
1. 将动物从笼中取出,放入诱导箱;先给予100%氧气2-3分钟,再调至4-5%异氟烷。
2. 持续观察,直至动物出现共济失调、俯卧、呼吸缓慢平稳且不动,标志麻醉起效。
3. 将动物移出诱导箱,立即用面罩或鼻罩罩住口鼻,以维持麻醉输送。
4. 把管路从诱导箱转接至面罩/鼻罩;将蒸发器调至1-3%异氟烷,流量计调至1L/min氧气,以维持麻醉。
5. 眼部涂凡士林基人工泪液软膏,防止角膜干燥。
6. 术前评估麻醉深度:观察呼吸频率、深度及对足趾夹捏的反应(踏板回缩反射)。必要时将蒸发器维持在1-3%,确保术中麻醉水平合适。
7. (可选)术后为补液,取预热至35–36°C的乳酸林格液或0.9%生理盐水,于肩胛间皮下注射。小鼠剂量10-40mL/kg(每点≤1mL),大鼠5-10mL/kg(每点≤5mL)。
8. 麻醉及恢复期间持续监测,至少每15分钟记录一次麻醉深度及呼吸频率,并形成书面记录,以便识别趋势、优化后续麻醉方案。
9. 手术结束后关闭蒸发器,给予100%氧气约5分钟。
Reference:
[1] Oh SS, Narver HL. Mouse and Rat Anesthesia and Analgesia. Curr Protoc. 2024;4(2):e995.
Cas No. | 26675-46-7 | SDF | |
别名 | 异氟醚 | ||
Canonical SMILES | FC(OC(Cl)C(F)(F)F)F | ||
分子式 | C3H2ClF5O | 分子量 | 184.5 |
溶解度 | DMF: miscible,DMSO: miscible,Ethanol: miscible,Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/ml | 储存条件 | Store at 2-8°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 5.4201 mL | 27.1003 mL | 54.2005 mL |
5 mM | 1.084 mL | 5.4201 mL | 10.8401 mL |
10 mM | 0.542 mL | 2.71 mL | 5.4201 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet